TITLE:
Improvement of Survival in Patient with Primary Metastatic Breast Cancer over a 10-Year Periode: Prospective Analyses Based on Individual Patient Date from a Multicenter Data Bank
AUTHORS:
Jana Barinoff, Florian Heitz, Sherko Kuemmel, Christine Dittmer, Rita Hils, Fatemeh Lorenz-Salehi, Alexander Traut, Andreas du Bois
KEYWORDS:
Breast Cancer; Primary Metastatic Breast Cancer; Therapy of Metastatic Breast Cancer; Survival of Metastatic Breast Cancer
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.4 No.8,
October
18,
2013
ABSTRACT: Approximately 6% of patients with
breast cancer have distant metastases at the time of the initial diagnosis. The
aim of this analysis was to examine the overall survival rate over time and to
investigate the effect of new therapy options. Methods: This retrospective analysis was
performed based on the data bank of the Clinic for Gynaecological Oncology/Dr.
Horst Schmidt Klinik, Wiesbaden and the Clinic for Gynaecological Oncology and
Senology/Kliniken Essen Mitte, Essen. The patients with primary metastatic
breast cancer (pmBC) who were diagnosed and treated at the accredited breast
cancer centres of these clinics were enrolled between 1998 and 2007. The date
of diagnosis was used to define 2 specifically chosen 5-year periods: 1998-2002
and 2003-2007. The follow-up time was on average 76 months. The Breslow Test
was used to evaluate changes in the median survival time and to detect factors
associated with the increase in survival rates. Results: Two hundred sixteen patients with
complete baselines were analysed. Ninety patients were diagnosed between 1998
and 2002, and 126 patients received their diagnosis of pmBC between 2003 and
2007. The tumour-biological factors were the same in both groups, whereas the
therapeutic concepts were different—the later group (2003-2007) received more
aromatase inhibitors, taxane-based chemotherapy and trastuzumab. This finding
resulted in an increased median survival time from 31 months in the years
1998-2002 to 44 months in the group with the first diagnosis between 2003 and
2007. Conclusions: Primary
metastatic breast cancer occurred at constant rates over last 10 years. The
tumour findings did not change in the time between the two examined groups;
however, the treatment options in the 2003-2007 group included newly approved
therapies. The time period of the first diagnosis was detected as a risk factor
for overall survival. Those patients diagnosed in the more recent time frame
had a significantly improved survival rate. The establishment of new therapy
options may explain this finding.